Jack Kiser
Story Poster
Notre Dame relying on new additions to replicate success of 2024
2 mo ago by Olin Buchanan
Notre Dame must replace its quarterback, three starting offensive linemen, two of its top receivers, its top two tacklers and its leader in sacks and interceptions. Even with so many departures, Marcus Freeman's Fighting Irish are projected to be a top-10 team.
Story Poster
Detailing important departures from Texas A&M's top 2025 opponents
5 mo ago by Olin Buchanan
As Mike Elko & Co. prepare for the 2025 football season, Olin Buchanan takes a deep dive into the losses that some of Texas A&M's biggest opponents are facing due to players' completion of eligibility, early entry to the NFL draft and those entering the transfer portal.
Story Poster
19:25
Nuño's Notes: Sharing South Bend intel from Notre Dame insiders
11 mo ago by David Nuño
Marcus Freeman's Notre Dame Fighting Irish enter the 2024 season ranked No. 7 in the nation and with CFP hopes. After speaking to some Notre Dame insiders, David Nuño shares some of the intel coming from South Bend as the Irish come to Aggieland this week.
Get access to all Premium content today
Start your subscription for just $1
Try Premium Now
Story Poster
Tale of the Tape: No. 20 Texas A&M vs. No. 7 Notre Dame
11 mo ago by TexAgs
Notre Dame's football program is steeped in tradition, with 11 claimed national titles and a seemingly two-deep of legends at every position. However, none of that will matter on Saturday night when the Irish walk into a packed, rowdy Kyle Field in Bryan-College Station.
Story Poster
Rebuilding offensive line primary concern for Notre Dame in 2024
1 yr ago by Olin Buchanan
In order to improve on a 10-3 finish, the Fighting Irish must continue its tradition of fielding a formidable offensive line. Success will also be contingent on Duke transfer quarterback Riley Leonard and their defense — which ranked fifth in 2023 — delivering productive seasons.
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.